Praxis Precision Medicines shareholders approve 870K share increase for 2020 equity plan

Praxis Precision Medicines, Inc.

Stockholders elected Dean Mitchell and Jill DeSimone as Class I directors for terms ending 2027.
Ratified Ernst & Young as independent auditor for FY 2024 with 15.3M votes for.
Approved amendment to 2020 Stock Plan, increasing authorized shares by 870,000 (9.1M for, 5.1M against).
Advisory vote on executive compensation passed with 10.0M for, 4.1M against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.